Thalidomide

Property	Information
Drug Name	Thalidomide
FDA Approval	Yes (for leprosy and multiple myeloma)
Used for	Investigational use in various cancers due to antiangiogenic and immunomodulatory properties
Clinical Trial Phase	Ongoing optimization of thalidomide analogues
Clinical Trial Explanation	Not specified
Common Side Effects	Deep vein thrombosis, peripheral neuropathy, constipation, somnolence, pyrexia, pain, teratogenicity
OS without	Not specified
OS with	Not specified; ongoing studies for cancer-specific outcomes
PFS without	Not specified
PFS with	Not specified; research focuses on enhancing therapeutic profiles while minimizing toxicity
Usefulness Rating	3
Usefulness Explanation	Not specified
Toxicity Level	4
Toxicity Explanation	Thalidomide, although it has shown promise in treating various cancers, has a high level of toxicity due to side effects such as deep vein thrombosis, peripheral neuropathy, constipation, somnolence, pyrexia, pain, and teratogenicity (risks to a developing fetus). As such, it's rated as 4 out of 5, with 5 being the most toxic. Keep in mind that these effects may vary from person to person, so it is important to discuss the risks and benefits with your healthcare provider.

Notes: Recent advances in thalidomide-related compounds target anticancer efficacy with reduced side effects. These developments suggest thalidomide analogues could become a promising therapeutic alternative for cancer treatment, enhancing the drug's applicability beyond its current FDA-approved uses. Continued research aims to refine these compounds to maximize benefits and minimize risks.

From Ben Williams Book: Not specified

Loading comments...